Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosapride citrate + rebamipide
- Development stage
- Phase 1
- Lead developer
- Ildong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Mosapride citrate + rebamipide** is a fixed-dose combination of two small-molecule drugs indicated primarily for the treatment of chronic atrophic gastritis (CAG). Mosapride is a gastroprokinetic agent that acts as a selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, enhancing gastric motility by promoting acetylcholine release and accelerating gastrointestinal transit[4][2]. It also acts as an antagonist at the 5-HT3 receptor via its major metabolite[4]. Rebamipide is a gastric mucosal protective agent that enhances mucosal defense by stimulating endogenous prostaglandin production, improving mucosal blood flow, inhibiting the generation of free radicals, suppressing cytokine production, and reducing neutrophil activation[6][3]. The combination is shown to provide superior efficacy in CAG treatment compared to mosapride monotherapy, with greater symptom improvement, pathological recovery, and beneficial changes in gastric mucosal biomarkers, without increasing adverse effects[1][2][3].
- Brand names
- Motireb
- Other names
- mosapride + rebamipide
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on mosapride citrate + rebamipide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosapride citrate + rebamipide.